Trajectories of Oral PrEP Adherence Among Young Kenyan Women: Implications for Promoting Effective PrEP Use.
Adherence
Kenya
PrEP
Trajectories
Journal
AIDS and behavior
ISSN: 1573-3254
Titre abrégé: AIDS Behav
Pays: United States
ID NLM: 9712133
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
accepted:
08
06
2022
pubmed:
17
7
2022
medline:
24
1
2023
entrez:
16
7
2022
Statut:
ppublish
Résumé
Using data from a 2-year study of young women at high HIV risk in Thika and Kisumu, Kenya, we identified group-based trajectories of PrEP adherence based on electronic pillcap-monitoring and assessed potentially associated demographic and socio-behavioral factors. Among 348 women, we selected a three-trajectory adherence model: low and declining (N = 211, 61%), moderate but declining (N = 119, 34%) and steady high adherers (N = 18, 5%). We also identified a two-trajectory HIV risk model based on self-perceived risk in the past week: high and increasing (N = 28, 8%) and steady low (N = 320, 92%) risk. The Kisumu site was associated with the moderate but declining and steady high adherence trajectories, while increasing VOICE risk score was associated with the low and declining adherence trajectory. We found no association between the adherence and risk trajectories. Our findings suggest adherence support may need tailoring by setting. Early, sustained support may also help those at highest risk of non-adherence. Utilizando datos de un estudio de dos años de duración en mujeres jóvenes con alto riesgo de VIH en Thika y Kisumu, Kenia, identificamos trayectorias grupales de adherencia a la PrEP basadas en el monitoreo electrónico de pillcap y evaluamos los factores demográficos, sociales y de comportamiento potencialmente asociados con la adherencia. En un grupo de 348 mujeres, seleccionamos un modelo de adherencia de tres trayectorias: baja y decreciente (N = 211, 61%), moderada pero decreciente (N = 119, 34%) y altas constantes (N = 18, 5%). También identificamos un modelo de riesgo de VIH de dos trayectorias basado en el riesgo autopercibido en la última semana: riesgo alto y creciente (N = 28, 8%) y riesgo bajo constante (N = 320, 92%). El sitio de Kisumu estuvo asociado con las trayectorias de adherencia alta moderadas pero decrecientes y constantes, mientras que el aumento de la puntuación de riesgo de VOICE se asoció con la trayectoria de adherencia baja y decreciente. No se encontró asociación entre la adherencia y las trayectorias de riesgo. Nuestros hallazgos sugieren que el apoyo a la adherencia podría individualizarse de acuerdo con el entorno. El apoyo temprano y sostenido a la adherencia también puede ayudar a las personas con mayor riesgo de no adherencia.
Autres résumés
Type: Publisher
(spa)
Utilizando datos de un estudio de dos años de duración en mujeres jóvenes con alto riesgo de VIH en Thika y Kisumu, Kenia, identificamos trayectorias grupales de adherencia a la PrEP basadas en el monitoreo electrónico de pillcap y evaluamos los factores demográficos, sociales y de comportamiento potencialmente asociados con la adherencia. En un grupo de 348 mujeres, seleccionamos un modelo de adherencia de tres trayectorias: baja y decreciente (N = 211, 61%), moderada pero decreciente (N = 119, 34%) y altas constantes (N = 18, 5%). También identificamos un modelo de riesgo de VIH de dos trayectorias basado en el riesgo autopercibido en la última semana: riesgo alto y creciente (N = 28, 8%) y riesgo bajo constante (N = 320, 92%). El sitio de Kisumu estuvo asociado con las trayectorias de adherencia alta moderadas pero decrecientes y constantes, mientras que el aumento de la puntuación de riesgo de VOICE se asoció con la trayectoria de adherencia baja y decreciente. No se encontró asociación entre la adherencia y las trayectorias de riesgo. Nuestros hallazgos sugieren que el apoyo a la adherencia podría individualizarse de acuerdo con el entorno. El apoyo temprano y sostenido a la adherencia también puede ayudar a las personas con mayor riesgo de no adherencia.
Identifiants
pubmed: 35841463
doi: 10.1007/s10461-022-03753-y
pii: 10.1007/s10461-022-03753-y
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
171-181Subventions
Organisme : NIMH NIH HHS
ID : K24 MH114732
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH109309
Pays : United States
Organisme : NIH HHS
ID : R01MH109309
Pays : United States
Investigateurs
Jessica E Haberer
(JE)
Jared M Baeten
(JM)
Elizabeth Bukusi
(E)
Nelly Mugo
(N)
Kenneth Ngure
(K)
Ruanne Barnabas
(R)
Harsha Thirumurthy
(H)
Ingrid Katz
(I)
Kevin Kamolloh
(K)
Josephine Odoyo
(J)
Linda Aswani
(L)
Lawrence Juma
(L)
Elizabeth Koyo
(E)
Bernard Rono
(B)
Stanley Cheruiot
(S)
Vallery Ogello
(V)
Loice Okumu
(L)
Violet Kwach
(V)
Alfred Obiero
(A)
Stella Njuguna
(S)
Millicent Faith Akinyi
(MF)
Lilian Adipo
(L)
Sylvia Akinyi
(S)
Catherine Kiptiness
(C)
Nicholas Thuo
(N)
Stephen Gakuo Maina
(SG)
Irene Njeru
(I)
Peter Mogere
(P)
Sarah Mbaire
(S)
Murugi Micheni
(M)
Lynda Oluoch
(L)
John Njoroge
(J)
Snaidah Ongachi
(S)
Jacinta Nyokabi
(J)
Lindsey Garrison
(L)
Maria Pyra
(M)
Kathleen K Thomas
(KK)
Nicholas Musinguzi
(N)
Susie Valenzuela
(S)
Susan Morrison
(S)
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
UNAIDS. Global HIV & AIDS statistics—Fact sheet. In; 2021.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410.
doi: 10.1056/NEJMoa1108524
Janes H, Corey L, Ramjee G, Carpp LN, Lombard C, Cohen MS, et al. Weighing the evidence of efficacy of oral PrEP for HIV prevention in women in Southern Africa. AIDS Res Hum Retroviruses. 2018;34:645–56.
doi: 10.1089/aid.2018.0031
Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, et al. A translational pharmacology approach to predicting outcomes of preexposure prophylaxis against HIV in men and women using tenofovir disoproxil fumarate with or without emtricitabine. J Infect Dis. 2016;214:55–64.
doi: 10.1093/infdis/jiw077
Karim SS, Kashuba AD, Werner L, Karim QA. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378:279–81.
doi: 10.1016/S0140-6736(11)60878-7
Marrazzo JM, Ramjee G, Richardson BA, Gomez K, Mgodi N, Nair G, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509–18.
doi: 10.1056/NEJMoa1402269
Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22.
doi: 10.1056/NEJMoa1202614
Celum C, Hosek S, Tsholwana M, Kassim S, Mukaka S, Dye BJ, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18: e1003670.
doi: 10.1371/journal.pmed.1003670
Nagin DS. Group-based modeling of development. Cambridge: Harvard University Press; 2005.
doi: 10.4159/9780674041318
Pasipanodya EC, Jain S, Sun X, Blumenthal J, Ellorin E, Corado K, et al. Trajectories and predictors of longitudinal preexposure prophylaxis adherence among men who have sex with men. J Infect Dis. 2018;218:1551–9.
doi: 10.1093/infdis/jiy368
Pyra M, Brown ER, Haberer JE, Heffron R, Celum C, Bukusi EA, et al. Patterns of oral PrEP adherence and HIV risk among Eastern African women in HIV serodiscordant partnerships. AIDS Behav. 2018;22:3718–25.
doi: 10.1007/s10461-018-2221-3
Sagaon-Teyssier L, Mabire X, Laguette V, Fressard L, Suzan-Monti M, Rojas Castro D, et al. A group-based trajectory model for changes in pre-exposure prophylaxis and condom use among men who have sex with men participating in the ANRS IPERGAY trial. AIDS Patient Care STDS. 2018;32:495–510.
doi: 10.1089/apc.2018.0081
Stoner MCD, Rucinski KB, Giovenco D, Gill K, Morton JF, Bekker LG, et al. Trajectories of PrEP adherence among young women aged 16 to 25 in Cape Town, South Africa. AIDS Behav. 2021;25(7):2046–53.
doi: 10.1007/s10461-020-03134-3
Haberer JE, Bangsberg DR, Baeten JM, Curran K, Koechlin F, Amico KR, et al. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015;29:1277–85.
doi: 10.1097/QAD.0000000000000647
Dunbar MS, Kripke K, Haberer J, Castor D, Dalal S, Mukoma W, et al. Understanding and measuring uptake and coverage of oral pre-exposure prophylaxis delivery among adolescent girls and young women in sub-Saharan Africa. Sex Health. 2018;15:513–21.
doi: 10.1071/SH18061
Bokoch K. HPTN 084 study demonstrates superiority of CAB LA to oral FTC/TDF for the prevention of HIV. 2020.
Bokoch K. HPTN 083 Study demonstrates superiority of cabotegravir for the prevention of HIV. 2020.
Haberer JE, Bukusi EA, Mugo NR, Pyra M, Kiptinness C, Oware K, et al. Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial. Lancet HIV. 2021;8:e130–7.
doi: 10.1016/S2352-3018(20)30307-6
Balkus JE, Brown E, Palanee T, Nair G, Gafoor Z, Zhang J, et al. An empiric HIV risk scoring tool to predict HIV-1 acquisition in African women. J Acquir Immune Defic Syndr. 2016;72:333–43.
doi: 10.1097/QAI.0000000000000974
Monahan PO, Shacham E, Reece M, Kroenke K, Ong’or WO, Omollo O, et al. Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living with HIV/AIDS in western Kenya. J Gen Intern Med. 2009;24:189–97.
doi: 10.1007/s11606-008-0846-z
Young CR, Kaida A, Kabakyenga J, Muyindike W, Musinguzi N, Martin JN, et al. Prevalence and correlates of physical and sexual intimate partner violence among women living with HIV in Uganda. PLoS ONE. 2018;13: e0202992.
doi: 10.1371/journal.pone.0202992
Rosenberg M, Schooler C, Schoenbach C. Self-esteem and adolescent problems: modeling reciprocal effects. Am Sociol Rev. 1989;54:1004–18.
doi: 10.2307/2095720
Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47:555–67.
doi: 10.1016/S0022-3999(99)00057-4
Pulerwitz J, Mathur S, Woznica D. How empowered are girls/young women in their sexual relationships? Relationship power, HIV risk, and partner violence in Kenya. PLoS ONE. 2018;13: e0199733.
doi: 10.1371/journal.pone.0199733
Jeyaseelan L, Kumar S, Mohanraj R, Rebekah G, Rao D, Manhart LE. Assessing HIV/AIDS stigma in south India: validation and abridgement of the Berger HIV Stigma scale. AIDS Behav. 2013;17:434–43.
doi: 10.1007/s10461-011-0128-3
Cherpitel CJ, Ye Y, Bond J, Borges G, Cremonte M, Marais S, et al. Cross-national performance of the RAPS4/RAPS4-QF for tolerance and heavy drinking: data from 13 countries. J Stud Alcohol. 2005;66:428–32.
doi: 10.15288/jsa.2005.66.428
Muthén B, Muthén LK. Integrating person-centered and variable-centered analyses: growth mixture modeling with latent trajectory classes. Alcohol Clin Exp Res. 2000;24:882–91.
doi: 10.1111/j.1530-0277.2000.tb02070.x
Reza-Paul S, Lazarus L, Jana S, Ray P, Mugo N, Ngure K, et al. Community inclusion in PrEP demonstration projects: lessons for scaling up. Gates Open Res. 2019;3:1504.
doi: 10.12688/gatesopenres.13042.1
Haberer JE, Mugo N, Baeten JM, Pyra M, Bukusi E, Bekker LG. PrEP as a lifestyle and investment for adolescent girls and young women in Sub-Saharan Africa. J Int Assoc Provid AIDS Care. 2019;18:2325958219831011.
doi: 10.1177/2325958219831011
Clinicaltrials.gov. PrEP My Way: A Novel PrEP Delivery System to Meet the Needs of Young African Women. Clinicaltrials.gov; 2020.
Nair G. Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study. IAS 2021; 2021.
Haberer JE, Baeten JM, Campbell J, Wangisi J, Katabira E, Ronald A, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10:e1001511–e1001511.
doi: 10.1371/journal.pmed.1001511
Roberts ST, Haberer J, Celum C, Mugo N, Ware NC, Cohen CR, et al. Intimate partner violence and adherence to HIV pre-exposure prophylaxis (PrEP) in African women in HIV serodiscordant relationships: a prospective cohort study. J Acquir Immune Defic Syndr. 1999;2016(73):313–22.
Beesham I, Heffron R, Evans S, Baeten JM, Smit J, Beksinska M, et al. Exploring the use of oral pre-exposure prophylaxis (PrEP) among women from Durban, South Africa as part of the HIV prevention package in a clinical trial. AIDS Behav. 2021;25:1112–9.
doi: 10.1007/s10461-020-03072-0
Khawcharoenporn T, Mongkolkaewsub S, Naijitra C, Khonphiern W, Apisarnthanarak A, Phanuphak N. HIV risk, risk perception and uptake of HIV testing and counseling among youth men who have sex with men attending a gay sauna. AIDS Res Ther. 2019;16:13.
doi: 10.1186/s12981-019-0229-z
Schaefer R, Thomas R, Nyamukapa C, Maswera R, Kadzura N, Gregson S. Accuracy of HIV risk perception in east Zimbabwe 2003–2013. AIDS Behav. 2019;23:2199–209.
doi: 10.1007/s10461-018-2374-0
Muwonge TR, Ngure K, Katabira E, Mugo N, Kimemia G, Burns BFOR, et al. Short message service (SMS) surveys assessing pre-exposure prophylaxis (PrEP) adherence and sexual behavior are highly acceptable among HIV-uninfected members of serodiscordant couples in East Africa: a mixed methods study. AIDS Behav. 2019;23:1267–76.
doi: 10.1007/s10461-018-2326-8
Musinguzi N, Muwonge T, Ngure K, Katabira E, Mugo N, Burns BFOR, et al. Comparison of short messaging service self-reported adherence with other adherence measures in a demonstration project of HIV preexposure prophylaxis in Kenya and Uganda. AIDS (London, England). 2018;32:2237–45.
doi: 10.1097/QAD.0000000000001955
Golub SA. Tensions between the epidemiology and psychology of HIV risk: implications for pre-exposure prophylaxis. AIDS Behav. 2014;18:1686–93.
doi: 10.1007/s10461-014-0770-7
Milne J, Brady H, Shato T, Bohn D, Mdladla M, Ngcwayi N, et al. Measuring HIV risk perception and behavior: results from round 1 of the cognitive interviewing project with young women and men who have sex with men in South Africa. AIDS Behav. 2020;24:2307–18.
doi: 10.1007/s10461-020-02790-9
Haberer JE, Kidoguchi L, Heffron R, Mugo N, Bukusi E, Katabira E, et al. Alignment of adherence and risk for HIV acquisition in a demonstration project of pre-exposure prophylaxis among HIV serodiscordant couples in Kenya and Uganda: a prospective analysis of prevention-effective adherence. J Int AIDS Soc. 2017;20:21842.
doi: 10.7448/IAS.20.1.21842
Gandhi M, Murnane PM, Bacchetti P, Elion R, Kolber MA, Cohen SE, et al. Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen. AIDS (London, England). 2017;31:2245–51.
doi: 10.1097/QAD.0000000000001615